{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:05:23Z","timestamp":1707523523215},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,8]]},"DOI":"10.7759\/cureus.13226","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:05:35Z","timestamp":1612821935000},"source":"Crossref","is-referenced-by-count":1,"title":["Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico"],"prefix":"10.7759","author":[{"given":"Juan Carlos","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier A","family":"Galnares-Olalde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"G\u00f3mez-Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adib","family":"Jorge de Sarachaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin Steven","family":"Vargas-Ca\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"18","author":"Carr AS","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010, 18:10-46. 10.1186\/1471-2377-10-46","journal-title":"BMC Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al.. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016, 87:419-425. 10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British Neurologists' management guidelines","volume":"15","author":"Sussman J","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of British Neurologists' management guidelines. Pract Neurol. 2015, 15:199-206. 10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09667-5","article-title":"Frequency and clinical features of treatment-refractory myasthenia gravis","volume":"267","author":"Rath J","year":"2020","unstructured":"Rath J, Brunner I, Tomschik M, et al.. Frequency and clinical features of treatment-refractory myasthenia gravis. J Neurol. 2020, 267:1004-1011. 10.1007\/s00415-019-09667-5","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan R","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard, DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017, 56:185-196. 10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns TM","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010, 74:1434-1440. 10.1212\/WNL.0b013e3181dc1b1e","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki A 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000, 55:16-23. 10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis ML","year":"2010","unstructured":"Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010, 3:93-105. 10.1177\/1756285609356135","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas MC","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019, 15:113-124. 10.1038\/s41582-018-0110-z","journal-title":"Nat Rev Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher G","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: extended prospective study results. Muscle Nerve. 2018, 58:452-455. 10.1002\/mus.26156","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson D","year":"2016","unstructured":"Anderson D, Phan C, Johnston WS, Siddiqi ZA. Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol. 2016, 3:552-555. 10.1002\/acn3.314","journal-title":"Ann Clin Transl Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner S","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA,  Frisell T, Press R, Piehl F. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020, 77:974-981. 10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues N","year":"2012","unstructured":"Collongues N, Casez O, Lacour A, Tranchant C, Vermersch P, de Seze J, Lebrun C. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve. 2012, 46:687-691. 10.1002\/mus.23412","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","volume":"266","author":"Singh N","year":"2019","unstructured":"Singh N, Goyal V. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study. J Neurol. 2019, 266:1596-1600. 10.1007\/s00415-019-09296-y","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"411","author":"Litchman T","year":"2020","unstructured":"Litchman T, Roy B, Kumar A, et al.. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. J Neurol Sci. 2020, 411:116690. 10.1016\/j.jns.2020.116690","journal-title":"J Neurol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26790","article-title":"Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis","volume":"61","author":"Lu J","year":"2020","unstructured":"Lu J, Zhong H, Jing S, et al.. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis. Muscle Nerve. 2020, 61:311-315. 10.1002\/mus.26790","journal-title":"Muscle Nerve"},{"key":"ref18","article-title":"BeatMG: phase II trial of rituximab in myasthenia gravis","author":"U.S. National Library of Medicine","year":"2018","unstructured":"U.S. National Library of Medicine. BeatMG: phase II trial of rituximab in myasthenia gravis. Yale University, New Haven, CT; 2018."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing S","year":"2019","unstructured":"Jing S, Lu J, Song J, et al.. Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. J Neuroimmunol. 2019, 332:216-223. 10.1016\/j.jneuroim.2019.05.004","journal-title":"J Neuroimmunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano V","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020, 91:392-395. 10.1136\/jnnp-2019-322606","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/51498-rituximab-in-refractory-myasthenia-gravis-experience-in-a-single-healthcare-center-in-mexico","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:13Z","timestamp":1707506773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/51498-rituximab-in-refractory-myasthenia-gravis-experience-in-a-single-healthcare-center-in-mexico"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.13226","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}